Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication

Antiviral Research

Volumn 58, Issue 3, 2003, Pages 253-263

  Pereira, Cândida F ^a   Paridaen, Judith T M L ^a   Rutten, Karla ^a   Huigen, Marleen C D G ^a   Van De Bovenkamp, Marja ^a   Middel, Jeena ^a   Beerens, Nancy ^b   Berkhout, Ben ^b   Schuurman, Rob ^a   Marnett, Lawrence J ^c   Verhoef, Jan ^a   Nottet, Hans S L M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human immunodeficiency virus; Non steroidal anti inflammatory drugs; Peripheral blood mononuclear cells; Real time Taqman polymerase chain reaction; Reverse transcription

Indexed keywords

2 (ACETOXYPHENYL)HEPT 2 YNYLSULFIDE; ANTIVIRUS AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOME; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INHIBITION KINETICS; LD 50; LYMPHOCYTE; MACROPHAGE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INDUCTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037987952     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00006-8     Document Type: Article

References (39)

1. Arts E.J., Wainberg M.A. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 38:1994;1008-1016.
2. Baba M. Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Res. 33:1997;141-152.
3. Beerens N., Berkhout B. In vitro studies on tRNA annealing and reverse transcription with mutant HIV-1 RNA templates. J. Biol. Chem. 275:2000;15474-15481.
4. Beerens N., Groot F., Berkhout B. Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription. Nucleic Acids Res. 28:2000;4130-4137.
5. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der N.J. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:1990;495-503.
6. Bourinbaiar A.S., Lee-Huang S. The non-steroidal anti-inflammatory drug, indomethacin, as an inhibitor of HIV replication. FEBS Lett. 360:1995;85-88.
7. Boven L.A., Gomes L., Hery C., Gray F., Verhoef J., Portegies P., Tardieu M., Nottet H.S. Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. J. Immunol. 162:1999;4319-4327.
8. Chou, T.C., Hayball, M.P., 1996. CalcuSyn: Windows Software for Dose-Effect Analysis. BIOSOFT, Cambridge, UK.
9. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
10. De Clercq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol. 10:2000;255-277.
11. Esté J.A., Schols D., De Vreese K., Van Laethem K., Vandamme A.M., Desmyter J., De Clercq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:1997;98-104.
12. Gao W.Y., Cara A., Gallo R.C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8925-8928.
13. Hammer S.M., Kessler H.A., Saag M.S. Issues in combination antiretroviral therapy: a review. J. Acquir. Immune Defic. Syndr. 7(Suppl. 2):1994;S24-S35.
14. Harrich D., Hooker B. Mechanistic aspects of HIV-1 reverse transcription initiation. Rev. Med. Virol. 12:2002;31-45.
15. Henry K., Erice A., Tierney C., Balfour H.H. Jr., Fischl M.A., Kmack A., Liou S.H., Kenton A., Hirsch M.S., Phair J., Martinez A., Kahn J.O. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19:1998;339-349.
16. Holland P.M., Abramson R.D., Watson R., Gelfand D.H. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7276-7280.
17. Hooker C.W., Lott W.B., Harrich D. Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. J. Virol. 75:2001;3095-3104.
18. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Garner C., Seibert K., Marnett L.J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science. 280:1998a;1268-1270.
19. Kalgutkar A.S., Kozak K.R., Crews B.C., Hochgesang G.P. Jr., Marnett L.J. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J. Med. Chem. 41:1998b;4800-4818.
20. Kaul M., Garden G.A., Lipton S.A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 410:2001;988-994.
21. Kopp E., Ghosh S. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science. 265:1994;956-959.
22. Mansky L.M. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology. 222:1996;391-400.
23. Max B., Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin. Infect. Dis. 30(Suppl 2):2000;S96-116.
24. McKeating J.A., McKnight A., Moore J.P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65:1991;852-860.
25. Moore J.P., McKeating J.A., Weiss R.A., Sattentau Q.J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 250:1990;1139-1142.
26. Palella F.J. Jr., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:1998;853-860.
27. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods. 20:1988;309-321.
28. Pereira, C.F., Nijhuis, M., de Graaf, M., den Dunnen, J., Wieffer, M., Boucher, C.A.B., Schuurman, R., submitted for publication. Novel assay for fitness analysis of drug-resistant human immunodeficiency virus-1.
29. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
30. Physician's Desk Reference, 2000. 54. PDR Medical Economics Company, Montvale, NJ.
31. Ramratnam B., Mittler J.E., Zhang L., Boden D., Hurley A., Fang F., Macken C.A., Perelson A.S., Markowitz M., Ho D.D. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6:2000;82-85.
32. Reddy B., Yin J. Quantitative intracellular kinetics of HIV type 1. AIDS Res. Hum. Retroviruses. 15:1999;273-283.
33. Schmidtmayerova H., Nuovo G.J., Bukrinsky M. Cell proliferation is not required for productive HIV-1 infection of macrophages. Virology. 232:1997;379-384.
34. Serradji N., Bensaid O., Martin M., Kan E., Dereuddre-Bosquet N., Redeuilh C., Huet J., Heymans F., Lamouri A., Clayette P., Dong C.Z., Dormont D., Godfroid J.J. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication. J. Med. Chem. 43:2000;2149-2154.
35. Snyder S., D'Argenio D.Z., Weislow O., Bilello J.A., Drusano G.L. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob. Agents Chemother. 44:2000;1051-1058.
36. St Clair M.H., Richards C.A., Spector T., Weinhold K.J., Miller W.H., Langlois A.J., Furman P.A. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 31:1987;1972-1977.
37. Trono D. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J. Virol. 66:1992;4893-4900.
38. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61:1990;213-222.
39. Zahran M.A., Kovacs L., El S.I., Pedersen E.B., Nielsen C. The potential of aspirin in prodrug synthesis: a new potential delivery system of AZT and FLT. Arch. Pharm. (Weinheim). 329:1996;417-420.